Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Oral Thin Film Drugs Market by Product (Oral Thin Film, Sublingual Film, Fully Dissolving Dental/Buccal Film, Transdermal Thin Film, Others) and by Disease indication (Schizophrenia, Migraine, Opioid Dependence, Nausea Vomiting, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03863

Pages: NA

Charts: NA

Tables: NA

Oral drug delivery is an essential part of drug delivery and pharmaceutical industry. People with a condition called dysphagia (difficulty in swallowing) require oral administration of drugs. Thus, oral thin film medication is developed for swift oral administration of drugs. To improve patient compliance various types of vaccines and hormones are developed by the market players.

Technological advancement in drug discovery and development processes, less bio-availability of solid drugs, and inaccurate dosage by liquid formulations is expected to boost the market growth for oral thin film drugs market. However, challenges related to drug development and massive research investment required for creation of simple and novel formulation is expected to hinder the market.

The global oral thin film drugs market is segmented based on product, disease indication, and geography. Based on product, the market is classified into oral thin film, transdermal thin film, and others. Oral thin films are further segmented into sublingual film and fully dissolving dental/buccal film. Based on disease indication, the market is categorized into schizophrenia, migraine, opioid dependence, nausea & vomiting, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. These regions are further analyzed across the globe at country level to determine the market size and forecast for each segment and sub-segment.

Comprehensive competitive analysis and profiles of major market players such as MonoSol Rx, Tesa Labtec GmbH, Pfizer, Inc., Novartis AG, Wolters Kluwer, Solvay, Allergan plc. Sumitomo Dainippon Pharma Co., Ltd., IntelGenx Corp, and Transition Therapeutics, Inc. are provided in this report.

Key Benefits

  • The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
  • Extensive analysis of the market is conducted by following key product positioning and monitoring the top competitors within the market framework.
  • It offers a quantitative analysis to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  • Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

 Key Market Segments

  • By Product
    • Oral Thin Film
    • Sublingual Film
    • Fully Dissolving Dental/Buccal Film
    • Transdermal Thin Film
    • Others
  • By Disease indication
    • Schizophrenia
    • Migraine
    • Opioid Dependence
    • Nausea & Vomiting
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • IntelGenx Corp
  • Transition Therapeutics, Inc.
  • Wolters Kluwer
  • Sumitomo Dainippon Pharma Co., Ltd.
  • MonoSol Rx
  • Pfizer, Inc.
  • Novartis AG
  • Solvay
  • Allergan plc.
  • Tesa Labtec GmbH

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: ORAL THIN FILM DRUGS MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Oral Thin Film

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Sublingual Film

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Fully Dissolving Dental/Buccal Film

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Transdermal Thin Film

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: ORAL THIN FILM DRUGS MARKET, BY DISEASE INDICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Disease Indication

    • 5.2. Schizophrenia

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Migraine

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Opioid Dependence

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Nausea And Vomiting

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Others

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: ORAL THIN FILM DRUGS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By Disease Indication

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Oral Thin Film Drugs Market

        • 6.2.5.1. Market Size and Forecast, By Product
        • 6.2.5.2. Market Size and Forecast, By Disease Indication

      • 6.2.6. Canada Oral Thin Film Drugs Market

        • 6.2.6.1. Market Size and Forecast, By Product
        • 6.2.6.2. Market Size and Forecast, By Disease Indication

      • 6.2.7. Mexico Oral Thin Film Drugs Market

        • 6.2.7.1. Market Size and Forecast, By Product
        • 6.2.7.2. Market Size and Forecast, By Disease Indication

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By Disease Indication

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Oral Thin Film Drugs Market

        • 6.3.5.1. Market Size and Forecast, By Product
        • 6.3.5.2. Market Size and Forecast, By Disease Indication

      • 6.3.6. Germany Oral Thin Film Drugs Market

        • 6.3.6.1. Market Size and Forecast, By Product
        • 6.3.6.2. Market Size and Forecast, By Disease Indication

      • 6.3.7. Italy Oral Thin Film Drugs Market

        • 6.3.7.1. Market Size and Forecast, By Product
        • 6.3.7.2. Market Size and Forecast, By Disease Indication

      • 6.3.8. Spain Oral Thin Film Drugs Market

        • 6.3.8.1. Market Size and Forecast, By Product
        • 6.3.8.2. Market Size and Forecast, By Disease Indication

      • 6.3.9. UK Oral Thin Film Drugs Market

        • 6.3.9.1. Market Size and Forecast, By Product
        • 6.3.9.2. Market Size and Forecast, By Disease Indication

      • 6.3.10. Russia Oral Thin Film Drugs Market

        • 6.3.10.1. Market Size and Forecast, By Product
        • 6.3.10.2. Market Size and Forecast, By Disease Indication

      • 6.3.11. Rest Of Europe Oral Thin Film Drugs Market

        • 6.3.11.1. Market Size and Forecast, By Product
        • 6.3.11.2. Market Size and Forecast, By Disease Indication

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By Disease Indication

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Oral Thin Film Drugs Market

        • 6.4.5.1. Market Size and Forecast, By Product
        • 6.4.5.2. Market Size and Forecast, By Disease Indication

      • 6.4.6. Japan Oral Thin Film Drugs Market

        • 6.4.6.1. Market Size and Forecast, By Product
        • 6.4.6.2. Market Size and Forecast, By Disease Indication

      • 6.4.7. India Oral Thin Film Drugs Market

        • 6.4.7.1. Market Size and Forecast, By Product
        • 6.4.7.2. Market Size and Forecast, By Disease Indication

      • 6.4.8. South Korea Oral Thin Film Drugs Market

        • 6.4.8.1. Market Size and Forecast, By Product
        • 6.4.8.2. Market Size and Forecast, By Disease Indication

      • 6.4.9. Australia Oral Thin Film Drugs Market

        • 6.4.9.1. Market Size and Forecast, By Product
        • 6.4.9.2. Market Size and Forecast, By Disease Indication

      • 6.4.10. Thailand Oral Thin Film Drugs Market

        • 6.4.10.1. Market Size and Forecast, By Product
        • 6.4.10.2. Market Size and Forecast, By Disease Indication

      • 6.4.11. Malaysia Oral Thin Film Drugs Market

        • 6.4.11.1. Market Size and Forecast, By Product
        • 6.4.11.2. Market Size and Forecast, By Disease Indication

      • 6.4.12. Indonesia Oral Thin Film Drugs Market

        • 6.4.12.1. Market Size and Forecast, By Product
        • 6.4.12.2. Market Size and Forecast, By Disease Indication

      • 6.4.13. Rest of Asia Pacific Oral Thin Film Drugs Market

        • 6.4.13.1. Market Size and Forecast, By Product
        • 6.4.13.2. Market Size and Forecast, By Disease Indication

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By Disease Indication

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Oral Thin Film Drugs Market

        • 6.5.5.1. Market Size and Forecast, By Product
        • 6.5.5.2. Market Size and Forecast, By Disease Indication

      • 6.5.6. South Africa Oral Thin Film Drugs Market

        • 6.5.6.1. Market Size and Forecast, By Product
        • 6.5.6.2. Market Size and Forecast, By Disease Indication

      • 6.5.7. Saudi Arabia Oral Thin Film Drugs Market

        • 6.5.7.1. Market Size and Forecast, By Product
        • 6.5.7.2. Market Size and Forecast, By Disease Indication

      • 6.5.8. UAE Oral Thin Film Drugs Market

        • 6.5.8.1. Market Size and Forecast, By Product
        • 6.5.8.2. Market Size and Forecast, By Disease Indication

      • 6.5.9. Argentina Oral Thin Film Drugs Market

        • 6.5.9.1. Market Size and Forecast, By Product
        • 6.5.9.2. Market Size and Forecast, By Disease Indication

      • 6.5.10. Rest of LAMEA Oral Thin Film Drugs Market

        • 6.5.10.1. Market Size and Forecast, By Product
        • 6.5.10.2. Market Size and Forecast, By Disease Indication

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. MonoSol Rx

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Tesa Labtec GmbH

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Pfizer, Inc.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Novartis AG

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Wolters Kluwer

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Solvay

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Allergan Plc.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Sumitomo Dainippon Pharma Co., Ltd.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. IntelGenx Corp

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Transition Therapeutics, Inc.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ORAL THIN FILM DRUGS MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL ORAL THIN FILM DRUGS MARKET FOR ORAL THIN FILM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL ORAL THIN FILM DRUGS MARKET FOR SUBLINGUAL FILM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL ORAL THIN FILM DRUGS MARKET FOR FULLY DISSOLVING DENTAL/BUCCAL FILM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL ORAL THIN FILM DRUGS MARKET FOR TRANSDERMAL THIN FILM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL ORAL THIN FILM DRUGS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL ORAL THIN FILM DRUGS MARKET, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL ORAL THIN FILM DRUGS MARKET FOR SCHIZOPHRENIA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL ORAL THIN FILM DRUGS MARKET FOR MIGRAINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL ORAL THIN FILM DRUGS MARKET FOR OPIOID DEPENDENCE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL ORAL THIN FILM DRUGS MARKET FOR NAUSEA AND VOMITING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL ORAL THIN FILM DRUGS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL ORAL THIN FILM DRUGS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA ORAL THIN FILM DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 17. U.S. ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 18. U.S. ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 19. CANADA ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 20. CANADA ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 21. MEXICO ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 22. MEXICO ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 23. EUROPE ORAL THIN FILM DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 24. EUROPE ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 25. EUROPE ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 26. FRANCE ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 27. FRANCE ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 28. GERMANY ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 29. GERMANY ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 30. ITALY ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 31. ITALY ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 32. SPAIN ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 33. SPAIN ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 34. UK ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 35. UK ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 36. RUSSIA ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 37. RUSSIA ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 38. REST OF EUROPE ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 39. REST OF EUROPE ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 40. ASIA-PACIFIC ORAL THIN FILM DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 41. ASIA-PACIFIC ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 42. ASIA-PACIFIC ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 43. CHINA ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 44. CHINA ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 45. JAPAN ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 46. JAPAN ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 47. INDIA ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 48. INDIA ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 49. SOUTH KOREA ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 50. SOUTH KOREA ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 51. AUSTRALIA ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 52. AUSTRALIA ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 53. THAILAND ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 54. THAILAND ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 55. MALAYSIA ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 56. MALAYSIA ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 57. INDONESIA ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 58. INDONESIA ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 59. REST OF ASIA PACIFIC ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 60. REST OF ASIA PACIFIC ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 61. LAMEA ORAL THIN FILM DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 62. LAMEA ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 63. LAMEA ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 64. BRAZIL ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 65. BRAZIL ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH AFRICA ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH AFRICA ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 68. SAUDI ARABIA ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 69. SAUDI ARABIA ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 70. UAE ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 71. UAE ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 72. ARGENTINA ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 73. ARGENTINA ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 74. REST OF LAMEA ORAL THIN FILM DRUGS, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 75. REST OF LAMEA ORAL THIN FILM DRUGS, BY DISEASE INDICATION, 2025-2033 ($MILLION)
  • TABLE 76. MONOSOL RX: KEY EXECUTIVES
  • TABLE 77. MONOSOL RX: COMPANY SNAPSHOT
  • TABLE 78. MONOSOL RX: OPERATING SEGMENTS
  • TABLE 79. MONOSOL RX: PRODUCT PORTFOLIO
  • TABLE 80. MONOSOL RX: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. TESA LABTEC GMBH: KEY EXECUTIVES
  • TABLE 82. TESA LABTEC GMBH: COMPANY SNAPSHOT
  • TABLE 83. TESA LABTEC GMBH: OPERATING SEGMENTS
  • TABLE 84. TESA LABTEC GMBH: PRODUCT PORTFOLIO
  • TABLE 85. TESA LABTEC GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. PFIZER, INC.: KEY EXECUTIVES
  • TABLE 87. PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 88. PFIZER, INC.: OPERATING SEGMENTS
  • TABLE 89. PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 90. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 92. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 93. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 94. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 95. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96. WOLTERS KLUWER: KEY EXECUTIVES
  • TABLE 97. WOLTERS KLUWER: COMPANY SNAPSHOT
  • TABLE 98. WOLTERS KLUWER: OPERATING SEGMENTS
  • TABLE 99. WOLTERS KLUWER: PRODUCT PORTFOLIO
  • TABLE 100. WOLTERS KLUWER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101. SOLVAY: KEY EXECUTIVES
  • TABLE 102. SOLVAY: COMPANY SNAPSHOT
  • TABLE 103. SOLVAY: OPERATING SEGMENTS
  • TABLE 104. SOLVAY: PRODUCT PORTFOLIO
  • TABLE 105. SOLVAY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106. ALLERGAN PLC.: KEY EXECUTIVES
  • TABLE 107. ALLERGAN PLC.: COMPANY SNAPSHOT
  • TABLE 108. ALLERGAN PLC.: OPERATING SEGMENTS
  • TABLE 109. ALLERGAN PLC.: PRODUCT PORTFOLIO
  • TABLE 110. ALLERGAN PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. SUMITOMO DAINIPPON PHARMA CO., LTD.: KEY EXECUTIVES
  • TABLE 112. SUMITOMO DAINIPPON PHARMA CO., LTD.: COMPANY SNAPSHOT
  • TABLE 113. SUMITOMO DAINIPPON PHARMA CO., LTD.: OPERATING SEGMENTS
  • TABLE 114. SUMITOMO DAINIPPON PHARMA CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 115. SUMITOMO DAINIPPON PHARMA CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. INTELGENX CORP: KEY EXECUTIVES
  • TABLE 117. INTELGENX CORP: COMPANY SNAPSHOT
  • TABLE 118. INTELGENX CORP: OPERATING SEGMENTS
  • TABLE 119. INTELGENX CORP: PRODUCT PORTFOLIO
  • TABLE 120. INTELGENX CORP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. TRANSITION THERAPEUTICS, INC.: KEY EXECUTIVES
  • TABLE 122. TRANSITION THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 123. TRANSITION THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 124. TRANSITION THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 125. TRANSITION THERAPEUTICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL THIN FILM DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ORAL THIN FILM DRUGS MARKET
  • FIGURE 3. SEGMENTATION ORAL THIN FILM DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ORAL THIN FILM DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALORAL THIN FILM DRUGS MARKET
  • FIGURE 11. ORAL THIN FILM DRUGS MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. ORAL THIN FILM DRUGS MARKET FOR ORAL THIN FILM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. ORAL THIN FILM DRUGS MARKET FOR SUBLINGUAL FILM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. ORAL THIN FILM DRUGS MARKET FOR FULLY DISSOLVING DENTAL/BUCCAL FILM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. ORAL THIN FILM DRUGS MARKET FOR TRANSDERMAL THIN FILM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. ORAL THIN FILM DRUGS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. ORAL THIN FILM DRUGS MARKET SEGMENTATION, BY BY DISEASE INDICATION
  • FIGURE 18. ORAL THIN FILM DRUGS MARKET FOR SCHIZOPHRENIA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. ORAL THIN FILM DRUGS MARKET FOR MIGRAINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. ORAL THIN FILM DRUGS MARKET FOR OPIOID DEPENDENCE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. ORAL THIN FILM DRUGS MARKET FOR NAUSEA AND VOMITING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. ORAL THIN FILM DRUGS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 27. COMPETITIVE DASHBOARD
  • FIGURE 28. COMPETITIVE HEATMAP: ORAL THIN FILM DRUGS MARKET
  • FIGURE 29. TOP PLAYER POSITIONING, 2024
  • FIGURE 30. MONOSOL RX: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. MONOSOL RX: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. MONOSOL RX: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. TESA LABTEC GMBH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. TESA LABTEC GMBH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. TESA LABTEC GMBH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. PFIZER, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. PFIZER, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. NOVARTIS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. NOVARTIS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. WOLTERS KLUWER: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. WOLTERS KLUWER: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. WOLTERS KLUWER: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. SOLVAY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. SOLVAY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. SOLVAY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. ALLERGAN PLC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. ALLERGAN PLC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. ALLERGAN PLC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. SUMITOMO DAINIPPON PHARMA CO., LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. SUMITOMO DAINIPPON PHARMA CO., LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. SUMITOMO DAINIPPON PHARMA CO., LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. INTELGENX CORP: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. INTELGENX CORP: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. INTELGENX CORP: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. TRANSITION THERAPEUTICS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. TRANSITION THERAPEUTICS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. TRANSITION THERAPEUTICS, INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Oral Thin Film Drugs Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved